[{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Cyclacel Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fadraciclib","moa":"CDK2\/9","graph1":"Oncology","graph2":"Phase I","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The Institute of Cancer Research \/ Cyclacel Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"The Institute of Cancer Research \/ Cyclacel Pharmaceuticals"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Oncology","graph2":"Undisclosed","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The Institute of Cancer Research \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"The Institute of Cancer Research \/ Inapplicable"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"The Institute of Cancer Research \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"The Institute of Cancer Research \/ Inapplicable"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avutometinib","moa":"||Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Oncology","graph2":"Phase II","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"The Institute of Cancer Research \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"The Institute of Cancer Research \/ Inapplicable"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1, 2 and 3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Institute of Cancer Research \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"The Institute of Cancer Research \/ Inapplicable"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Ellipses Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EP0042","moa":"FLT3\/Aurora kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"The Institute of Cancer Research \/ Ellipses Pharma","highestDevelopmentStatusID":"7","companyTruncated":"The Institute of Cancer Research \/ Ellipses Pharma"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Nuvectis Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NXP800","moa":"HSF-1 pathway","graph1":"Oncology","graph2":"Phase I","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Institute of Cancer Research \/ The Institute of Cancer Research","highestDevelopmentStatusID":"6","companyTruncated":"The Institute of Cancer Research \/ The Institute of Cancer Research"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BAY1895344","moa":"Serine\/threonine-protein kinase ATR (FRP1)","graph1":"Oncology","graph2":"Phase I","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Institute of Cancer Research \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"The Institute of Cancer Research \/ Bayer AG"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"NeoPhore","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Institute of Cancer Research \/ The Institute of Cancer Research","highestDevelopmentStatusID":"4","companyTruncated":"The Institute of Cancer Research \/ The Institute of Cancer Research"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Apollo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Institute of Cancer Research \/ The Institute of Cancer Research","highestDevelopmentStatusID":"2","companyTruncated":"The Institute of Cancer Research \/ The Institute of Cancer Research"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Apollo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"The Institute of Cancer Research \/ The Institute of Cancer Research","highestDevelopmentStatusID":"2","companyTruncated":"The Institute of Cancer Research \/ The Institute of Cancer Research"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Capivasertib","moa":"||Serine\/threonine-protein kinase AKT","graph1":"Oncology","graph2":"Phase III","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Institute of Cancer Research \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"The Institute of Cancer Research \/ AstraZeneca"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Oracle Cancer Trust","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PLX4720","moa":"||Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"The Institute of Cancer Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Institute of Cancer Research \/ Oracle Cancer Trust","highestDevelopmentStatusID":"4","companyTruncated":"The Institute of Cancer Research \/ Oracle Cancer Trust"}]

Find Clinical Drug Pipeline Developments & Deals by The Institute of Cancer Research

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : The collaboration will use NeoPhore's proprietary small molecule inhibitors of DNA mismatch repair to investigate single agent activity against tumours with defined genetic backgrounds.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          April 18, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : NeoPhore

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Apollo Therapeutics is advancing a pipeline of therapeutic programmes based on breakthrough discoveries. The company identifies and develops pre-clinical and clinical stage assets with strong biological hypotheses and the potential to become meaningful n...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 28, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Recipient : Apollo Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : The collaboration combines the strengths and resources of both organisations to bring forward the development of novel therapies for cancer patients worldwide.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          November 14, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Recipient : Apollo Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          04

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : NXP800 is an oral small molecule inhibitor of the Heat Shock Factor 1 (HSF1) pathway, that plays an important role in the initiation and progression of many cancers, is currently in a Phase 1 clinical study.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 03, 2022

                          Lead Product(s) : NXP800

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Nuvectis Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : The treatment combination comprised VS-6766 and defactinib, which can potentially hinder signals ovarian cancer to grow. VS-6766 is a dual RAF/MEK inhibitor of Verastem Oncology while defactinib is a FAK inhibitor.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 19, 2021

                          Lead Product(s) : Avutometinib,Defactinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Study suggests that therapies which target CD38-such as the multiple myeloma drug daratumumab-could hold promise against prostate cancer too, by reawakening the anti-cancer immune response.

                          Product Name : Darzalex

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          July 05, 2021

                          Lead Product(s) : Daratumumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : The OlympiA trial showed that adding olaparib for one year following standard treatment for patients who had an inherited BRCA mutation and early-stage, HER-2 negative breast cancer, cut the risk of their breast cancer returning by 42 per cent at a media...

                          Product Name : Lynparza

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 06, 2021

                          Lead Product(s) : Olaparib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : Ellipses Pharma has rapidly progressed the development of EP0042 following successful negotiations between the ICR and the company, which were led by our Business and Innovation Office.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 19, 2021

                          Lead Product(s) : EP0042

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Ellipses Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : The ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 showed promise in patients with a range of advanced, heavily pre-treated cancers, including breast, bowel, and prostate tumors in a dose-escalation portion of a first-in-human phase 1...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 28, 2020

                          Lead Product(s) : BAY1895344

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Bayer AG

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          CPhI Korea
                          Not Confirmed
                          CPhI Korea
                          Not Confirmed

                          Details : First trial to use the pioneering genetically targeted drug olaparib - already licensed for ovarian, breast and prostate cancer - together with a promising new medicine, called capivasertib.

                          Product Name : Lynparza

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 14, 2020

                          Lead Product(s) : Olaparib,Capivasertib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank